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Abstract
Background: Cancer is a proliferation disease affecting a genetically unstable cell population, in which molecular
alterations can be somatically inherited by genetic, epigenetic or extragenetic transmission processes, leading to a
cooperation of neoplastic cells within tumoural tissue. The efflux protein P-glycoprotein (P-gp) is overexpressed in
many cancer cells and has known capacity to confer multidrug resistance to cytotoxic therapies. Recently, cell-to-
cell P-gp transfers have been shown. Herein, we combine experimental evidence and a mathematical model to
examine the consequences of an intercellular P-gp trafficking in the extragenetic transfer of multidrug resistance
from resistant to sensitive cell subpopulations.
Methodology and Principal Findings: We report cell-to-cell transfers of functional P-gp in co-cultures of a P-gp
overexpressing human breast cancer MCF-7 cell variant, selected for its resistance towards doxorubicin, with the
parental sensitive cell line. We found that P-gp as well as efflux activity distribution are progressively reorganized
over time in co-cultures analyzed by flow cytometry. A mathematical model based on a Boltzmann type integro-
partial differential equation structured by a continuum variable corresponding to P-gp activity describes the cell
populations in co-culture. The mathematical model elucidates the population elements in the experimental data,
specifically, the initial proportions, the proliferative growth rates, and the transfer rates of P-gp in the sensitive and
resistant subpopulations.
Conclusions: We confirmed cell-to-cell transfer of functional P-gp. The transfer process depends on the gradient of
P-gp expression in the donor-recipient cell interactions, as they evolve over time. Extragenetically acquired drug
resistance is an additional aptitude of neoplastic cells which has implications in the diagnostic value of P-gp
expression and in the design of chemotherapy regimens.
Reviewers: This article was reviewed by Leonid Hanin, Anna Marciniak-Czochra and Marek Kimmel.
Introduction
Current view on cancer
In essence, cancer is a proliferation disease affecting a
genetically unstable cell population. The somatic muta-
tion theory, which is the prevailing paradigm, stipulates
that cancer arises from a stepwise accumulation of
changes in genes that progressively drives subclonal
neoplastic cells to evolve independently from the others,
escaping from proliferation control and competing for
space and resources and, finally, to kill the host. The
key feature is that the cancer-promoting changes are
intrinsic molecular events that are i) inheritable by
daughter cells and ii) selectable, in the sense that they
confer selective advantage in the cell population envir-
onment [1,2]. The essential set of aptitudes that a cell
must acquire to become malignant includes self-
sufficiency of growth factors, resistance to death signals,
evasion from apoptosis, limitless replicative potential,
sustained angiogenesis, and proclivity for tissue invasion
and metastasis [2]. It is also widely recognized that
genetic instability results in the creation of diverse
daughter cells, capable of interaction with the cell
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erties of a heterogeneous tissue [3].
Within such tumour tissue, molecular alterations are
considered to be somatically inherited by genetic, epige-
netic (traits that are not dependent on the primary
sequence of DNA) or extragenetic (post-translational
protein modifications that initiate and support positive
feedback loops) transmission processes [1], leading to a
cooperation of neoplastic cells [4].
Role of P-glycoprotein in breast cancer
Despite decades of research, breast cancer remains a
major public health issue. Worldwide, breast cancer
represents 23% of overall female cancers and accounts
for 40,000 deaths each year in the United States alone.
Currently, the lifetime risk of developing a breast cancer
for women born in the United States is 1 in 8. For
metastatic forms of breast cancers, the 5-year relative
survival is only 26% [5] and complete remission has
been estimated as low as 3.1% after this period [6].
Response to first-line chemotherapies span from 30 to
65% and are followed, after a period varying from 6 to
10 months, by disease progression [7]. In fact, resistance
to chemotherapy is believed to cause treatment failure
in 90% of metastatic breast cancer patients [8].
Resistance to chemotherapy is related to the overall
mechanisms that are involved in a decrease of drug effi-
cacy against tumours [9]. Among these factors, proteins
lowering the intracellular concentration of chemothera-
peutics and belonging to the ATP-binding Cassette
(ABC) transporters are well-known for their specific
responsibility [10]. These membrane proteins are charac-
terized by their ability to efflux a large panel of both che-
mically and functionally unrelated compounds
comprising potent cytotoxics currently used in chemo-
therapeutic treatments. Consequently, tumours overex-
pressing this type of energy-dependent pump have been
very early identified on the basis of their Multi-Drug
Resistance (MDR) phenotype [11]. The P-glycoprotein
(P-gp) was the first drug-efflux protein characterized
[12]. With the growing number of molecularly cloned
ABC transporters (48 different genes up to now have
been identified in the human genome), a rational nomen-
clature have been proposed. Meta-analysis [13] or immu-
nochemistry studies [14] have determined that
approximately 40% of all breast cancer tumours express
ABCB1/MDR1 coded P-gp. ABCB1/MDR1 gene expres-
sion has a prognostic value for cell resistance to antican-
cer drugs [15,16] and for treatment failure [17].
Genetic versus extragenetic resistance transmission
Until now, the development of multi-drug resistance in
neoplastic cells was explained as the consequences of
two main mechanisms. On one hand, cells natively
expressing drug-efflux proteins retain their phenotype
throughout the process of malignant transformation. On
the other hand, in non-expressing cells, chemotherapeu-
tics have been shown first to induce P-gp expression
and, second, to exert a selection of resistant cells during
the course of chemotherapy [18-21]. Therefore, P-gp
induction was considered to only depend on the cell
type and/or the previous history of exposure to cyto-
toxics. Biomathematical models have been proposed to
describe the kinetics of P-gp induction as a function of
tissue cytotoxic concentration [22] with the objective of
adapting the time course of drug administration to over-
come as much as possible multidrug resistance.
Recently however, extragenetic transmissions of multi-
drug resistance have been reported. These unexpected
events all involve direct transfers of P-gp to ABCB1/
MDR1 non-expressing recipient cells from various mul-
tidrug resistance donors, namely adherent cell lines in
vitro and in vivo [23], stromal cells isolated from
patients suffering of ovarian cancers [24] and lympho-
blastic leukemia cells in suspension [25]. These findings
actually add a new modality of resistance appearance,
and possibly spreading, in a population of tumour cells.
Theoretically, cell-to-cell P-gp transfers in conditions of
antineoplastic treatment could confer a significant
advantage to sensitive cells, keeping them alive long
enough to produce their own P-gp copies, under the
induction process, and thus, to resist chemotherapy.
However, the real dynamics of extragenetic acquired
resistance in a growing population of cancer cells has
remained, until now, unknown. Herein, we propose a
biomathematical model, derived from a previous analysis
[26], supported by experimental parameters and invol-
ving processes of i) cell proliferation and death, ii) P-gp
induction and degradation and iii) cell-to-cell P-gp
transfer, to help answer this question. A parallel study
in progress will present experimental data on mechanics
of transfer [27]. The present model was supplied by new
data obtained in vitro from MCF-7 human breast adeno-
carcinoma, a cell line that has previously been shown to
be capable of intercellular P-gp transfer [23]. The main
objectives of the present work were to investigate the
influence of both cancer cell line intrinsic factors
(growth rate, initial proportions of sensitive and resis-
tant cells, and P-gp transfer rate), as well as treatment
management parameters (i.e. cycles of drug administra-
tion), on overall multidrug resistance, both genetically
and extragenetically transmitted.
Results
MCF-7 proliferation and resistance
In 2005, Levchenko et al. have shown that several drug
sensitive cell lines, including the well-established human
breast adenocarcinoma cells MCF-7, are able to acquire
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cellular transfer of the resistance protein P-gp from a
derived mdr1-transfected cell line. In the present work,
the consequences of P-gp transfers in MCF-7 were stu-
died by using, as a P-gp donor, a cell line variant
obtained by selection for resistance to doxorubicine
(Doxo) and therefore called MCF-7/Doxo. MCF-7/Doxo
have previously been shown to overexpress P-gp, to be
resistant to doxorubicin andt oe f f l u xP - g p - s u b s t r a t e
fluorescent probes in a verapamil and cyclosporine
A-sensitive manner [28].
Resistance phenotypes were first assessed both in
MCF-7 and MCF-7/Doxo by determining growth rates
in the presence of increasing Doxo concentrations (0,
0.1, 0.3, 1, 3 and 10 μM). As seen in Figure 1, without
treatment, MCF-7 and MCF-7/Doxo displayed very
similar growth rates, 0.6195 and 0.6328 per day, respec-
tively. These values correspond to a doubling time of
26.8 and 26.3 hours, for sensitive and resistant cells,
respectively. In the presence of Doxo (0.1-3 μM), the
proliferation rates of MCF-7/Doxo were not significantly
modified. By contrast, MCF-7 cells were strongly
affected by the treatment, the growth rates passing
through 0.0316 per day at 0.1 μM Doxo and decreasing
very rapidly to -0.7492 per day with 3 μM Doxo.
Transfers of P-gp and efflux activity in co-cultures
In order to investigate potential transfers of P-gp between
cells, 50% of non P-gp-expressing parental MCF-7 cells
were co-cultured with 50% of their multidrug resistant
counterpart MCF-7/Doxo. Obvious morphological differ-
ences allow distinction of MCF-7 from MCF-7/Doxo var-
iants in the monolayer under phase contrast microscopy
(Figure 2). After attachment to the tissue culture treated
dish, MCF-7 were characterized by markedly birefringent
membrane margins, while MCF-7/Doxo were more spread
with dark edges and flat cell bodies. Following several days
of growing in co-culture, we noticed a singular and stable
spatial organization consisting in the formation of MCF-7
islets encased in a layer of MCF-7/Doxo.
A first approach used to detect a potential intercellu-
lar P-gp transfer was direct immunodetection of P-gp in
living cells in the co-cultures, by using a phycoerythrin-
conjugated monoclonal antibody directed against an
epitope localized in an extracellular loop of the protein
[29]. Membrane P-gp content was followed over time,
from day 0 to day 6, by flow cytometry. As shown in
Figure 3A, the peak corresponding to non P-gp-expressing
M C F - 7a td a y0p r o g r e s s i v e l yd r i f t e dt ot h er i g h tf r o m
3.60 ± 0.53 (n = 10) to 14.53 ± 2.34 (n = 4, mean S.E.M.)
arbitrary fluorescence units at day 6 of co-cultures, in
our experimental conditions. In addition, the total mass
of P-gp remained unchanged over time for 10,000
analyzed cells (Figure 3C). Thus, it is suggested that the
distribution of P-gp within the cell population was reor-
ganized with time but that the balance between P-gp bio-
synthesis and degradation remained constant, in average,
in the samples.
Figure 1 Proliferation and resistance of MCF-7 variants in culture. Growth curves of MCF-7 (A) and MCF-7/Doxo (B) were established over
5,5 days. Cells were grown in the absence or presence of doxorubicin (0.1 to 10 μM, corresponding symbols given in the legend in B) and
counted every 12 hours in a Malassez chamber. Cell counts are expressed as the logarithm of the cell numbers at various times (N) divided by
the cell number at day 0 (N0).
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tional drug resistance, the ability of co-cultured cells to
efflux calceinAM, a P-gp substrate probe which is a pre-
cursor of the fluorescent dye calcein, was assayed again
by flow cytometry. In these experiments, cell fluores-
cence accumulation is therefore an inverse function of
P-gp activity. Symmetrically to what observed with
membrane P-gp content, the peak of fluorescence corre-
sponding to initially sensitive cells, with a high calcein
concentration, was also progressively shifted, but to the
left, towards regions of less fluorescence accumulation
(Figure 3B). The fluorescence values decreased from
2553 ± 227 (n = 9) at day 0 to 322 ± 31 (n = 21, mean ±
S.E.M.) at day 6 of co-cultures. These cells therefore
acquired an aptitude to efflux the fluorescent dye. How-
ever, by contrast with Figure 3A, the activity distribution
is additionally characterized by the appearance of a third
subpopulation displaying an intermediate efflux activity.
This middle peak increased in amplitude with time to
reach 32.5 ± 1.6% of the cells at day 6 of co-cultures (n =
21, mean ± S.E.M.). Concurrently, the peak amplitudes
corresponding to the subpopulations of MCF-7 with
higher and, especially, lower calcein concentrations
slightly declined. Interestingly, the total mass of activity
(Figure 3D) also remained constant with time.
Although the progressive shift towards regions of
higher membrane P-gp content, concurrently with the
appearance of higher efflux activities, are observations
that can be accounted for by effective P-gp transfer in
co-cultures, the exact origin of these protein and activity
redistributions had to be clarified. It should be first
mentioned that, in our experiments, such phenomena
are never observed in cells cultured separately. Never-
theless, in co-cultures, various cell interactions as well
as secretion of soluble factors, could be responsible for
microenvironmental regulations resulting in a decrease
in P-gp expression in MCF-7/Doxo. Such phenomena
could result in P-gp and activity redistributions, consis-
tent with results observed in the preceding experiments.
To investigate these points, it was necessary to distin-
guish and to follow both MCF-7 variants in co-cultures.
Thus, parental sensitive MCF-7 cells were tagged with
the persistent dye Cell Tracker Blue (ctbMCF-7) before
mixture with MCF-7/Doxo and co-culture. As seen in
Figure 4, upon one day of co-culture, a population of
ctbMCF-7 appeared also positive to P-gp detection with
Figure 2 Spatial organization of MCF-7 and MCF-7/Doxo in co-cultures. To obtain phase contrast micrographs of growing MCF-7 variants in
co-cultures, dishes were seeded with a 50:50 mixture of MCF-7:MCF-7/Doxo at day 0. Morphological differences permit an immediate
identification of each cell subpopulation. MCF-7 appeared birefringent and round (boxes) whereas MCF-7/Doxo are more flat and spread
(ellipses). Note that the cells remained organized in well-delimited islets.
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cancer cell line. A-B, A 50:50 MCF 7:MCF 7/Doxo cell mixture was seeded on cultures dishes at day 0 and co-cultured. P-gp expression was
immunodected by using a PE-conjugated UIC2 monoclonal antibody (A) and P-gp activity was followed with calceinAM as a fluorescent probe
(B) after 0, 3, 4, 5 and 6 days of co-culture. In both cases (A & B) a sample of 10 000 cells was analyzed. In order to reduce the stochastic
fluctuations, normalized binned logarithmic histograms were built from all-events list-mode raw data (see methods). In A, the peak (on the left
side) of MCF-7 expressing low levels of P-gp corresponds to the sensitive cells. The peak on the right side corresponds to MCF-7/Doxo resistant
cells. In B, the peak (on the right side) corresponds to the low efflux activity of sensitive MCF-7 cells, and the peak on the right corresponds to
the MCF-7/Doxo resistant cells. C-D, total mass (sum of collected fluorescence light of a sample) of P-gp (C) and efflux activity (D) in co-cultures
have been computed through days 0, 3, 4, 5 and 6 for 10 000 events analyzed by flow cytometry.
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tion appeared to be relatively stable over 3 days of co-
culture, even though dilution of Celltracker blue within
successive ctbMCF-7 generations weakened the signal
and did not allow us to distinguish cell subpopulations
further. In these experiments we also noticed conti-
nuous variation of phycoerythrin fluorescence in
co-cultured ctbMCF-7, suggesting a progressive acquisi-
tion of P-gp by sensitive parental MCF-7, rather than a
decrease of P-gp expression in MCF-7/Doxo. The possi-
bility that dual positive events were, in fact, artifactual
doublets of ctbMCF-7+MCF-7/Doxo can be excluded
because the cytometry analysis was triggered on the
electronic Coulter-type cell volume (EV) channel. Cell
diameters in quadrants Q1, Q2 and Q4 matched to
values corresponding to individual MCF-7 or MCF-7/
Doxo cells (Figure 5).
Taken together, these results strongly suggest the
occurrence of a mechanism of transfer i) involving only
a small fraction of the membrane content in protein of
the donor cells but conferring a significant efflux activity
to the recipient cells and ii) exhibiting a continuous
exchange mode simply dependent on the gradient, i.e.
the net difference in P-gp expression levels separating
the cells under concern. In order to test these hypoth-
eses and to evaluate their consequences in the dynamics
of multidrug resistance within a cell culture, a mathe-
matical transfer model was developed.
Figure 4 Flow cytometry detection of P-gp transfers in tagged parental MCF-7. Parental sensitive MCF-7 were tagged with the persistent
fluorescent probe CellTracker Blue (ctbMCF-7), prior to co-cultures. ctbMCF-7 alone, extemporaneous mixtures of 50:50 ctbMCF-7:MCF-7/Doxo or
co-cultures at various times were analyzed after labelling with the PE-conjugated UIC2 monoclonal antibody. Scatter plots were obtained by
quantifying CellTacker Blue content the FL1 channel and P-gp immunodetection in the FL2 channel. A, pure ctbMCF-7. B, pure MCF-7/Doxo. C,
extemporaneous mixture of ctbMCF-7:MCF-7/Doxo. D-F, co-cultures obtained from 50:50 ctbMCF-7:MCF-7/Doxo, after 1 to 3 days. All analysis
were performed with unchanged excitation light power and photomultipliers voltage settings. The quadrant limits were set in order to obtain
less than 1% of double positive cells (Q2) in the analysis of the sample C. Despite a progressive loss of FL1 signal, due to Celltracker blue
dilution within daughter ctbMCF-7, a population of dually labelled cells appeared in the upper right quadrant. Percentages indicate the fraction
of cells having a double positive labelling in quadrant Q2.
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To quantify the transfer of P-gp activity, which is
assumed to result in a gain of resistance, we have used a
mathematical model, presented in the material and
methods section and derived from Hinow et al. (2009).
In the absence of cytotoxics and according to Figure 1,
the growth rate is independent of the P-gp content.
Herein, the growth rate was thus assumed to be identi-
cal for MCF-7 and MCF-7/Doxo in co-culture (r =0 . 6 3
day
-1).
The transfer rate τ, the transfer efficiency f, and the
thresholds δmin < δmax were estimated by using intensive
parameter estimation computations. The conditioned
flow cytometry activity distribution (see material and
methods) at day 0 was used as an input for the numeri-
cal simulation of the model.
The best fit to data distribution at day 6 was estimated
by using the least square minimization method over
100,000 different values of the parameters (Figure 6). An
algorithm was implemented to search for the minimal
Euclidian distance between the experimental data and
the numerical simulations at day 6. More precisely, we
used the experimental data to define the initial distribu-
tion and to compute the solution of theoretical model.
Then, we looked for the parameters providing the mini-
mal Euclidian distance between the theoretical distribu-
tion and the experimental one at day 6.
Conclusively, the model is coherent with the existence
of cell-to-cell resistance transfers, since the best fit of
the parameters gives τ = 0.4, and f = 0.2, corresponding
to non-null transfer rate and efficiency. The parameters
of the model, the respective methods used to determine
their numerical values and the associated symbols are
given in Table 1.
Fitted parameters seem to indicate that some limita-
tions, or constraints, occurred for transfers between
cells in our experimental conditions. First, the transfers
were not homogeneous over the whole assortment of
activities expressed by cells within the co-cultures. In
this respect, a threshold δmin distinct from 0 suggests
that transfers did not occur or were not detected when
P-gp activities of the cells were to close. In addition,
since the threshold δmax is not equal to the maximal
value 10
4, transfers did not arise either in case of
extreme activity differences. This implies the occurrence
of a permissible range of activities governing the optimal
transfers between donor and recipient cells. Moreover, a
transfer rate of τ = 0.4 means that transfer events
occurred in average every 1/ τ = 2.5 days for each cell
in our experiments. Finally, the quantity of transferred
activity globally corresponds to a fraction f = 0.2 of the
difference between the activity of the donor and recipi-
ent cell.
Consequences of resistance activity transfers on model
response to chemotherapeutic cycles in co-cultures
Fast acquisition of P-gp activity by doxorubicin-sensitive
MCF-7 in a population of growing tumoural cells may
be of first relevance to determine the dynamics of
response to chemotherapy. Thus, to test the significance
of P-gp transfers within a co-culture of sensitive and
resistant cells, simulations were carried out by using our
mathematical model of activity transfers, fed with biolo-
gical data.
Figure 5 Distribution of cell diameters in parental sensitive, multidrug resistant and transferred MCF-7 populations. The histograms
correspond to cell diameters in quadrants Q1 (CellTracker Blue positive cells, left), Q4 (UIC2 positive cells, middle) and Q2 (double positive cells,
right) of Figure 4. Quantitative values give cells volumes of 1984 ± 51 μm
3 for parental sensitive MCF-7, 1776 ± 41 μm
3 for multidrug resistant
MCF-7/Doxo and 2398 ± 39 μm
3 for transferred MCF-7 (mean ± coefficient of variation).
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meters determined in vitro, in particular the growth
rates of monolayers and the transfer parameters. There-
fore, cell proliferation was artificially high in abstraction
of any physiological environment and the growth curves
obtained by simulation should not be considered as data
clinically exploitable. Likewise, practical aspects of treat-
ment administration involving pharmacokinetics of dox-
orubicin (such as elimination half-life, drug clearance,
volumes of distribution) were ignored. The simulated
treatment was simplified into a bolus of 1 μM doxorubi-
cin that reaches the maximum concentration in the
extracellular compartment with no delay and maintains
the same level over 10 days. Then, the treatment was
interrupted for 4 days (i.e. doxorubicin concentration is
zero). The treatment cycled every 14 days for 4 cycles.
A ss h o w ni nF i g u r e7 A ,t h en u m b e ro fp u r es e n s i t i v e
MCF-7 in a simulated culture declined progressively in
the presence of Doxo during the first 10 days of a treat-
ment cycle and, thereafter, increased during the 4-days
interruption at rates r(pmin) corresponding to the values
previously determined (Figure 1). To follow the respec-
tive populations of sensitive and resistant cells within
the simulated co-cultures, a particular attention should
be paid to the criterion used to define what exactly a
sensitive cell is (resistant cells being considered as the
complement). Herein, we defined sensitive cells as
MCF-7 having a negative growth rate in the presence of
1 μM doxorubicin. The growth rate r is supposed to
vary only as a function of the overall P-gp activity p
(intrinsic activity and activity acquired or lost by trans-
fers), as presented in supporting Figure 7B. As a conse-
quence, transferred sensitive cells with enough P-gp
activity to have a positive growth rate will be considered
as resistant cells.
The evolution of the simulated co-cultures was extre-
mely dependent on the initial distribution of cells, i.e.
the relative proportions of cells of with different P-gp
contents. Again, as for the estimation of transfer para-
meters, the biological data distribution in term of efflux
activity p at day 0, was used as an input template for
computer simulations. However, the simulations were
started with inocula of 10
4 cells (corresponding to an
approximate mass of 0,01 mg) comprising only a small
proportion of resistant cells, 0.1% (i.e. 10 cells, Figures
8A&8B), or 1% (i.e. 100 cells, Figures 8C&8D). For each
condition, the numbers of sensitive, resistant and total
cells were plotted as a function of time in two situa-
tions: without or with cell-to-cell P-gp activity transfers.
In the absence of transfer (Figure 8A&8C), resistant
cells grew linearly, and represented after few days the
majority of the cells in the co-cultures. The number of
sensitive cells decreased during the treatment and
increased during the interruption phases. In these simu-
lations, the initial distribution of sensitive cells was
based on low efflux activities analyzed by flow cytome-
try. As a consequence, the population of sensitive cells
did not correspond to a single ray but was rather repre-
sented by a bell curve shape encompassing a spectrum
Figure 6 Estimation of parameters for the transfer model.T h i s
graph corresponds to the distribution of P-gp activity at day 6 of
co-culture. The initial distribution of P-gp activity at day 0 (not
shown here) was obtained from a mixture of 50:50 MCF-7:MCF-7/
Doxo cells analyzed by cytometry as in Figure 4. The transfer model
was run over 6 days. The dotted curve corresponds to the efflux
activity of the co-culture measured at day 6, and the solid curve
corresponds to the distribution of activity derived from model. The
fitting parameters are given above the curves and were obtained by
least squares minimization.
Table 1 List of the model parameters, their significations, values and symbols
Symbol Interpretation Value Units Method
r Growth rate of cells in absence of drug 0.63 day
-1 measured
c Drug concentration 0 or 1 μM set
τ Rate of transfer of P-gp activity 0.4 day
-1 fitted
F Activity transfer efficiency 0.2 - fitted
δmin Minimum threshold for transfers 10
1.4 fluorescence unit fitted
δmax Maximum threshold for transfers 10
1.9 fluorescence unit fitted
The column method refers to the approach employed to determine their respective numerical value.
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cent units. Consequently, from a cycle to another, the
sensitive cells having the less negative growth rates were
selected by the treatment. For that reason, the popula-
tion of sensitive cells decreased to a minimum and,
then, increased again by growing during treatment inter-
ruptions while the growth rates converged to zero dur-
ing the doxorubicin phases.
In the presence of transfers (Figure 8B&8D), results
d i f f e r e df r o ma b o v ea n dw e r eg r e a t l yi n f l u e n c e db yt h e
initial number of resistant cells in the inoculum. In fact,
with transfers during treatment, growth rates of resistant
and sensitive cells converged to an intermediate value,
due to a loss of activity by resistant combined with a
gain of activity by sensitive cells. With initial conditions
corresponding to 0.1% or 1% of resistant cells, after an
initial phase during the first treatment, the growth rates
of the cell population tend to become analogous. The
main observation is that transfers significantly decreased
the growth rate of the whole cell population exposed to
cytotoxics, especially when the co-culture is initiated
with a relative large proportion (1%) of resistant cells.
Discussion
In the present work, we observe effective transfers of
P-gp and efflux activity from a P-gp overexpressing
MCF-7 human breast cancer cell line variant, selected
for its resistance towards doxorubicin, to the parental
sensitive cell line. Our results thus confirm the work of
Levchenko et al. (2005) conducted in vivo and also
in vitro o ns e v e r a la d h e r e n tc e l ll i n e s ,i n c l u d i n gMDR1-
transfected MCF-7 [24]. Functional transfers of P-gp
have also been described very recently between leukemic
cells cultured in suspension [25]. In addition, the possi-
bility for a malignant cell of inheriting P-gp from a nor-
m a lc e l lw a ss h o w nb yR a f i iet al. in a study where
sensitive ovarian cancer cells acquired P-gp by interac-
tion with particular stromal cells isolated from the peri-
toneal cavity of patients [24]. To our best knowledge,
the present work and the three above cited references
are the first reports describing extragenetic direct cell-
to-cell transfers of P-gp. Among these lines, it should be
mentioned that an intercellular transfer of the drug
resistance phenotype was first reported indirectly in a
pioneering study of Frankfurt et al. [30].
The present data highly reinforce the fact that the
P-glycoprotein, a 170 kDa polypeptide consisting of
1280 amino acids that spans 12 times the cell mem-
brane [31], can be exchanged from a donor cell to a
recipient one, keeping its ability to efflux drugs and,
thus, conferring the MDR phenotype. In addition to the
discovery of the ability, for cells, to transfer huge inte-
gral membrane proteins, these important findings also
reveal the occurrence of an additional extragenetic
mechanism to acquired chemoresistance, in the absence
of pressure selection, in vitro. The possible occurrence
of such P-gp transfers in vivo may be crucial to under-
stand P-gp expression in breast cancers. In this context,
Figure 7 Growth rate of sensitive cell as a function of P-gp content. A, computer simulation giving the number of sensitive MCF-7 versus
time during a chemotherapy regimen, cycling every 14 days, with 10 days of 1 μM doxorubicin treatment followed by 4 days of interruption,
for 4 cycles. The initial simulated tumour consisted in 10
4 MCF-7 having growth rates corresponding to r(pmin). B, plot giving the growth rates r
as a function of the P-gp-driven calceinAM efflux activity p for cells exposed to 1 μM doxorubicin. The function describing r(p) is used in the
simulations presented Figure 8. All cells having a negative growth rate are considered as sensitive MCF-7.
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sion in human breast tumours are known to suffer of
considerable variability across studies, as revealed by a
compendium based on 31 articles compiling results
obtained mainly by immunodetection methods onto
1,200 breast carcinomas [13]. The discrepancies in the
literature were ascribed in a large extent to a lack of rig-
orous methodology, preparation of samples as well as
anti-P-gp antibodies varying from a study to another
[32,33]. Some immunohistological studies carried out in
normal breast collected from healthy donors failed to
find P-gp expression [34,35]. However, by using a more
sensitive approach, namely RT-PCR research for P-gp
transcripts, low but significant levels of P-gp mRNAs
have been detected in normal tissues adjacent to che-
motherapy-naïve tumours [36]. Importantly, low basal
Figure 8 Computer simulation giving the consequences of cell-to-cell P-gp activity transfers in co-cultures exposed to doxorubicin,
according to the mathematical model. A chemotherapy regimen is simulated by cyclic exposure of an inoculum of 10
4 cells to 1 μM
doxorubicin. The treatment cycled every 14 days, with 10 days of doxorubicin treatment followed by 4 days of interruption, for 4 cycles. The
initial proportions of resistant MCF-7/Doxo vary form 0,1% (A&B )t o1 %( C&B ). Simulations were performed in situations where transfers were
abolished (A & C) or permitted (B & D) with the parameters determined in Figure 6. For each condition, the numbers of sensitive, resistant and
total cells are plotted versus time. Sensitive MCF-7 are defined as cells having negative growth rate in the presence of 1 μM doxorubicin (see
Figure 7).
Pasquier et al. Biology Direct 2011, 6:5
http://www.biology-direct.com/content/6/1/5
Page 10 of 18levels of P-gp efflux activities have been shown to be
sufficient enough to contribute extensively to drug resis-
tance, in vitro [37]. In this context, the levels of P-gp
activities heritable by P-gp transfers and found in the
present study are largely compatible with a resistance
increase in vivo. The time-course of P-gp transfers,
detectable between the third and the fourth day in co-
culture, is also short enough to overcome the effects of
cytotoxics used in chemotherapy.
The particular spatial organization of MCF-7 in co-
cultures has certainly severe consequences on the con-
tact surfaces between sensitive and resistant cells. As
seen under microscopic observation, cells were not
organized as a homogeneous mixture of well-separated
cell variants, but rather in delimited islets of sensitive
settling aside from resistant cells. As a result, transfers
between the most separated populations in term of che-
moresistance (full sensitive versus full resistant cells)
may occur only at the frontier of islets in case of cell-
to-cell contact-dependent transfers [23,24], keeping in
mind that transfers can also arise between cells of inter-
mediate P-gp levels. From this, it is assumed that the
transfer process is a rather complicated phenomenon in
which spatial structures bring limitations. Such spatial-
constraint or regulated P-gp transfers may provide an
additional rationale to the heterogeneity of P-gp expres-
sion previously observed in studies carried out on het-
erogeneous tumour samples [13,33]. Additional studies
focused on mechanisms of P-gp transfers are needed to
go further concerning that point.
As a matter of fact, our approach to quantify the para-
meters of transfers by using biomathematical modelling,
points out some constraints, revealed by the parameters
fitted to the biological data. The mathematical model
has been constructed to i) be applicable to a population
of interacting cells in proliferation, ii) to consider the
cell population as a continuum density structured by the
quantity p of transferable P-gp activity and iii) to have
rules governing transfer. The rules of the transfer pro-
cess have been delineated and discussed in detail in a
companion paper [26]. The better fit was obtained by
using the activity transferred from resistant to sensitive
cells, undirected and directed shifts being neglected.
Herein, we consider that P-gp activity is a better estima-
tion of therapy resistance as compared to P-gp expres-
sion, because activity is directly responsible for
resistance to cytotoxic drugs. Moreover, this choice
allows us to use directly the model to simulate the
response of a co-culture to chemotherapeutic cycles (see
below). Nevertheless, a correlation between P-gp levels
and activity has been described in several cell lines
[15,38,39]. Parameters fitting revealed quantitative
aspects of P-gp activity transfer, in particular a transfer
rate τ corresponding to one event every 2.5 days, a value
to be compared to the doubling time of MCF-7 close to
1 day. In addition, the calculation of the average activity
and the average level of P-gp expression over the time
in a co-culture showed that theses values remain stable
throughout the experiments. We conclude that there is
neither significant gain nor loss of efflux activity and P-
gp expression during the co-culture experiments. As a
consequence, the changes in the fluorescence distribu-
tions (for both P-gp and activity) can be attributed to
transfers, which are not rare phenomena compared to
the cell cycle duration. However, in a culture of growing
cells transferring P-gp, the topology of the exchange
network is constantly changing. This aspect is not taken
into consideration in the transfer model which does not
adapt rules of transfer as a function of time. The estima-
tion of the transfer rate τ is therefore a coarse estima-
tion that should be re-evaluated in future works
including spatial dynamics.
The model gives also a transfer efficiency f = 20%,
corresponding to the amount of activity transferred each
time with regard to the absolute activity difference
between the donor and recipient cells, and two transfer
thresholds, that can be viewed as bottom and top activ-
ities delimiting authorized transfers. These parameters
can be related to the life span of potential transfer vec-
tors, that are constructed and destroyed for instance, or
to the size of single P-gp cargos. Concerning this point,
it has been shown that high density P-gp microdomains
alter local properties of lipid membrane environment
and promote P-gp clustering [40]. In this respect, biolo-
gical data as well as transfer parameter f suggest an
organized quantal transfer of P-gp, in which the mini-
mum unit of exchange would probably consist in a clus-
ter of several copies of the transporter. Several
intercellular carriers have been proposed to be involved
in P-gp transfers. In adherent cells lines, close contacts
between donor and recipient cells have been shown to be
required [23,24]. In the other, in a model of liquid tumour,
P-gp containing microparticles released by resistant cells
and bound to sensitive cells, have been isolated [25]. The
possibility that both mechanisms actually co-exist in our
cell line is examined in an independent study [27].
The model was used to simulate and to quantify the
consequences of P-gp activity transfers on the cell distri-
bution within a growing co-culture during exposure
cycles to cytotoxics. More precisely, the model was fed
with biological data corresponding to sensitivity of
MCF-7 variants to doxorubicin. Doxorubicin is among
the preferred agents used in chemotherapy regimens for
preoperative breast tumour reduction, adjuvant treat-
ment after a first line surgical lumpectomy/mastectomy
and radiotherapy of invasive breast carcinoma or sys-
temic treatment of recurrent or metastatic breast can-
cers [41]. Doxorubicin is administrated alone or in
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lations, the concentration of doxorubicin was set at
1 μM, a value corresponding to the weekly supplemen-
tation of MCF-7/Doxo culture medium. This concentra-
tion is also close to the levels of doxorubicin found in
tumours under chemotherapy, reported to vary in the
10-0,1 μM range depending on the time separating the
administration of the drug to the measures [42-44].
The major consequence of P-gp activity transfers is
that subpopulations of sensitive and resistant cells
were no longer compartmentalized. Via P-gp activity
transfers, flows of cells depopulate and repopulate
resistant and sensitive cell s .T h i sw a so b v i o u so n c et h e
second cycle of treatment began, where the population
of sensitive cells increased by adjunction of cells com-
ing from resistant cells, which lose P-gp activity. Con-
versely, sensitive cells acquired P-gp activity and, thus,
developed progressively positive growth rates during
the treatment phases. When the number of donor cells
was increased up to 1%, the resulting exchanges of P-
gp caused a significant loss of activity for the resistant
cells. Acquisition of P-gp activity was therefore slowed
down for sensitive cells. As a result, in that case, the
numbers of sensitive and resistant cells within the co-
culture converged (became close) with time and the
overall growth rate of the cell population was reduced
(compared to all the other situations), giving a co-cul-
ture with fewer cells at the end of the four chemother-
apeutic cycles. In our model, the gain of P-gp is
central for survival and growth of non P-gp expressing
cells whereas the loss of P-gp by resistant cells has
predominant effects on the overall growth rate of the
simulated tumour. We also conclude that the initial
proportion of resistant cells in a population has a great
influence on the growth of the whole population in the
presence of transfer.
The present study sheds new light on fundamental
features underlying extragenetic acquisition of multi-
drug resistance in vitro, with a particular attention
given to quantitative aspects. Globally, P-gp transfers
led to an integration of the responses to the drug
across the cell population and a ‘collective’ phenotype
different than the sum of parts. However, MCF-7/
Doxo represents an extreme case of P-gp overexpres-
sion and fast growing cells. Future work should be
conducted with cells expressing intermediate amounts
of efflux activity, since transfers have been demon-
strated to be dependent on the P-gp levels [23]. More-
over, an improved mathematical model taking into
account evolving 2D or 3D spatial considerations has
to be developed together. Physiopathological implica-
tions of cell-to-cell protein transfers may be crucial,
especially if other membrane proteins and various cell
types are concerned.
Material and Methods
Cell lines
The cell lines used in the present study were the wild-type
drug-sensitive human breast adenocarcinoma MCF-7, pur-
chased at the American Type Culture Collection (LGC stan-
dards, Molsheim, France), and a multi-drug resistant MCF-
7/Doxo variant, kindly provided by Pr. J.-P. Marie (Hôtel
Dieu, Paris, France). The cells were grown in RPMI 1640
medium supplemented with 5% heat-inactivated fetal bovine
serum, 2 mM L-glutamine, and 1% antibiotic/antimycotic
solution. Doxorubicin (1 μM) was added to the culture med-
ium for the maintenance of the multi-drug resistant pheno-
type of MCF-7/doxo cells. Cultured cells were incubated at
37°C under a water-saturated 95% air-5% CO2 atmosphere.
Exposure of MCF-7/Doxo to the P-gp inhibitors verapamil
or cyclosporine A dose-dependently abolished both resis-
tance to doxorubicin and P-gp activity in MCF-7/doxo [28].
For proliferation assays, cells were plated at 10
5 per 60 X
15 mm tissue culture dish with or without doxorubicin.
Cells were dissociated by treatment with trypsin/EDTA
and then counted in a Malassez chamber. Cell proliferation
was followed every 12 hours during six days.
Analysis of P-gp expression and activity by flow
cytometry
Cultured or co-cultured MCF-7 were trypsin-resuspended
and washed with HBSS before analysis. For intercellular
P-glycoprotein transfer studies, P-gp was labelled using a
phycoerythrin (PE)-conjugated UIC2 mAb (Beckman
Coulter France, Villepinte, France). The fluorescent light
(FL) was quantified using a Cell Lab Quanta SC MPL flow
cytometer (Beckman Coulter) equipped with a 22 mW
488 nm excitation laser. Voltage settings of photomulti-
pliers were not modified throughout the experiments.
Each analysis consisted in a record of 10 000 events, trig-
gered on electronic volume (EV) as primary parameter,
according to a particle diameter exceeding 8 μm. Red
fluorescence was measured in FL2 channel (log scale)
through a 575 nm band pass emission filter. More than
93.1 ± 0.4% (mean ± standard error of the mean) of gated
events exhibited a FL2 > 1 for MCF-7/Doxo.
To study P-gp activity, resuspended cells were loaded
with 0.25 μM calcein acetoxy-methylester (Invitrogen
Life Technologies, Carlsbad, CA) in RPMI for 15 min at
37°C in the dark. Green FL was quantified via the FL1
channel (log scale) through a 525 nm band pas filter.
Controls of MCF-7, MCF-7/Doxo and extemporaneous
mixtures of 50:50 MCF-7: MCF-7/doxo were analysed
before co-cultures, in all experiments.
Analysis of P-gp by flow cytometry transfer in tagged
MCF-7
75%-confluent sensitive MCF-7 were loaded with 25 μM
of the cell-permeant reactive fluorescent dye CellTracker
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(Invitrogen Life Technologies, Carlsbad, CA) for 2 hour
at 37°C in 25 cm² culture dishes. The cells are then
washed twice with HBSS and covered with fresh com-
plete culture medium. Either CellTracker Blue loaded
sensitive MCF-7 (ctbMCF-7), or MCF-7/doxo, or a care-
fully homogenized 50:50 mixture of ctbMCF-7:MCF-7/
doxo were plated at the desired density on 60 mm cul-
ture dishes and analysed by flow cytometry after labelling
using the PE-conjugated UIC2 mAb, as described before.
Flow cytometry data conditioning and normalization
Accurate fitting of the mathematical model to flow cyto-
metry all-events histograms required raw data noise
reduction. Thus, list-mode data were segregated into
binned logarithmic histograms, with a bin width of 0.05
in log scale of arbitrary fluorescence units. The distribu-
tions were normalized, by scaling to an integral area of
1.0, in order to obtain a density of probability.
Mathematical model of P-gp activity transfer
In this section, we describe a mathematical model that
has been developed and used to describe the conse-
quences of a cell-to-cell P-gp protein transfer in terms
of multidrug resistance activity. Herein, the resistance
activity is viewed as the ability of a cell to efflux cyto-
toxics, which is considered to be correlated to the num-
ber of P-gp copies within the cell membrane.
Our modeling approach views the transfer of P-gp
proteins between cells as a stochastic process in which
individual transfer events are represented in a conti-
nuum population density function u(t,p), where t is time
and p is the quantity of P-gp on individual cell mem-
branes. The density function u(t,p) is the solution of an
integro-partial differential equation of Boltzmann type,
which describes an evolving population behavior as an
average of individual transfer events governed by speci-
fied rules. The aggregate transfer behavior is modeled as
an integral operator, with a kernel specified by the
transfer rules, acting on the continuum density. We
assume individual transfer events arise randomly (Rule
A1), occur at a specified average rate (Rule A2), and are
delimited by parameters specific to allowable quantities
of P-gp transferred between paired cells (Rules A3 and
A4) (see below). The large number of cells and proteins
involved justifies our assumption that a continuum
population density function describes the dynamic trans-
fer processes.
Rules for the transfer model:
￿ (A1) The probability that a pair of individuals is
involved in a transfer event is independent of their
P-gp values, and the pairing is chosen randomly
from all individuals.
￿ (A2) The time between two transfer events follows
an exponential law with mean τ-1 > 0 (alternatively,
τ is the rate of transfer per unit time).
￿ (A3) Let 0 <f < 1 (we call f the transfer efficiency). A
transfer between two individuals, one with value P-gp1
and the other with value P-gp2, results in a transfer of
the fraction f of their difference f |P-gp1 - P-gp2|
gained by the smaller and lost by the larger of the two.
￿ (A4) An exchange takes place only if the difference
of the transfer pair P-gp1 and P-gp2 in assumption
(A3) is > δ (we call δ Î (0, 1) the transfer threshold).
We decompose the construction of the model by con-
sidering separately the process of i) cell proliferation
and death, ii) P-gp induction and degradation rate, both,
at the cell and the population level, and iii) P-gp trans-
fer between cells. We consider p the P-gp efflux activity
of a cell, functionally measured by the loss of calcein
fluorescence for a resistant cell compared to a sensitive
one, and we introduce u(t,p) the density of cells at time
t having a P-gp activity p. In the sequel, for a given cell,
the fluorescence p is assumed to be a function of P-gp
expression on the cell surface.T h i sf u n c t i o ni ss t r i c t l y
increasing.
The terminology “density of cells with respect to p”
means that, if p1 < p2 are two quantities of P-gp activity,
then the number of cells with a P-gp activity in between
p1 < p2 at time t is
According to the fluorescence scale used in cytometry,
p varies between pmin =1and pmax =1 0
4, and the total
number of cells is given by
Ut utpd p
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In order to describe the time course of the cell distri-
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∂
∂
=+ ⋅ − (
utp
t
putp Tut utp
(, )
()(, ) ((,) ) (, ) 
proliferation
   2 ) ) ∈()
=∈ +
P-gp transfer
   
,,
(,) () (,
p
upu pL
11 0
01 1 0
4
0
14 ) ).
In this model the proliferation term combines the cell
division and mortality of cells, which is assumed to
depend on the activity p of P-gp only during the treat-
ment. Robin type boundary conditions are introduced to
preserve the total number of individuals when only the
drift process takes place (i.e. r = 0 and τ = 0). The term
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in [26]. The parameter τ describes the time between two
consecutives transfers, and the transfer operator T is
defined by
T
pf p p p f p p d p
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4). The main idea in the construction of the trans-
fer operator T is to derive the probability of a recipient
partner to acquire a level p of P-gp in a transfer event
from all possible donor partners. To describe a transfer
event we use the following rule: if a cell C1 and a cell
C2 have, respectively, a quantity p1 and p2 of P-gp activ-
ity before transfer, then, after transfer, C1 (respectively,
C2) will have an activity p1-f(|p1-p2|)(p2-p1) (respectively,
p2-f(|p1-p2|)(p1-p2)). So the fraction transferred is
f(|p1-p2|), which depends on the absolute value of the
difference between p1and p2 (the distance between the
P-gp activities of C1 and C2). The model is used with
constraints that correspond to a admissible interval
(δmin, δmax)f o r|p1-p2| to allow transfer. As a conse-
quence, when |p1-p2|<δmin or |p1-p2|>δmax there is
no transfer (i.e. f(|p1-p2|) = 0) and otherwise a constant
fraction is transferred (i.e. f(|p1-p2|) = s). Therefore, the
parameter 0 < s < 1 is called the transfer efficiency, and
0 ≤ δmin < δmax are called the transfer thresholds.
In the above model, the cell distribution of P-gp is
assumed to be homogeneous in space. In practice the
spatial distribution of P-gp can play an important role
in the transfer process. Here we neglect this aspect. This
problem will be investigated elsewhere.
Reviewers’ Comments
Reviewer 1: Leonid Hanin, Idaho State University,
Department of Mathematics, United States of America
This is an important and well-written paper that deals
with the efflux P-glycoproteins (P-gp), exchange of P-gp
between cells including a mathematical model of this
process, and the role of the P-gp transfer in bringing
about extragenetic resistance to chemotherapeutic treat-
ment of breast cancer.
1. General Comments
1. I think more biological discussion of P-gp activity and
the nature of P-gp transfer is warranted. In particular,
what is the time scale for transfer processes and is the
level of cellular P-gp activity heritable?
Quantitative values, relatively to arbitrary fluorescent
units given by flow cytometry, are now added in the
results in term of heritable cellular protein and activity,
as well. This question and the point concerning the time
scale for transfers are also discussed more extensively.
2. To put formation of chemotherapeutic drug resis-
tance into a more practical perspective, it would be help-
ful to mention whether normal breast tissue cells display
P-gp based efflux activity and whether P-gp exchange
may occur between normal and malignant cells.
The one and only article showing a possibility of P-gp
transfers between normal and cancer cells is the report
of Rafii et al. (2008) detailed at the beginning of the dis-
cussion. The possible basal P-gp activites in normal
breast and its consequences in terms of MDR are dis-
cussed p18.
3. Pp. 7-8. The mathematical model is introduced too
abruptly. I believe the authors should write a paragraph
or two about underlying general assumptions, the “big”
stochastic picture behind their model, explain the for-
mula for the transfer operator including the role of nor-
malization in more detail, and give stochastic
interpretation of coefficient τ.
A part concerning data conditioning and normaliza-
tion has been added p7 in Methods section. We have
also modified the presentation of the model, recalling the
precise assumptions for the transfer process.
4. P. 8. The paper deals with the model of P-gp trans-
fer with ε = h = 0. Given the predominantly biological
readership of the journal, I think it would be better to
omit these terms in the model and refer the reader to
paper [20] for a more general model accounting for dif-
fusion and drift.
We agree with the referee, and we modified the system
accordingly to the comment.
5. Paper [20] establishes the existence, under certain
simplifying assumptions, of the limiting equilibrium dis-
tribution of P-gp activity. What is it in a slightly more
general case of two thresholds considered in the present
work (in the absence of cell proliferation)? How fast is
this equilibrium reached? Is this relaxation process
slower or faster than cell cycling?
The two threshold case was in fact also considered in
the paper by Hinow et al. Up to now the authors did not
study the speed of convergences to the equilibrium distri-
butions (which is indeed a difficult question). In the pre-
sent model the cell cycle is simplified but includes the
growth rate of cells (neglecting the oscillation induced by
the cell cycle). This problem will be considered in future
works.
6. What are the relative effects of P-gp transfer and
cell proliferation on chemotherapeutic activity of
DOXO? One can compare survival of two-compartment
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Page 14 of 18tumor cell population exposed to DOXO under two sce-
narios: (1) no cell proliferation, just P-gp exchange and
(2) cell proliferation alone assuming equilibrium distri-
bution of P-gp activity. This would give some idea about
the net effect of P-gp transfer.
Indeed we did not consider the point (1) since in can-
cer the case with no cell proliferation does not arise.
Point (2) corresponds to Figure 8A&8C, where cell
growth of a two-compartment tumor cell population was
plotted without transfer.
7. It is not enough to say that model parameters were
“estimated by using intensive parameter estimation com-
putations”. Which experimental data were used for model
fitting? How was the method of least squares implemen-
ted? What weights were used, if any? Also, what are the
confidence limits or standard deviations of model para-
meters? If the confidence intervals are too wide the
reported parameter estimates may be misleading.
This point has been detailed.
8. References [22-44]-46] were never mentioned in the
text. Am I missing a supplement to the paper?
Corrected.
2. Technical Comments
1. P. 7, last line. “... fluorescence p is assumed to be a
function of P-gp expression on the cell surface.” It is
important to emphasize that this function is strictly
increasing.
OK, this has been added.
2. P. 9, lines 6-7 from below. Shouldn’t the sign of the
transfer terms be plus in both cases? Otherwise, if p1 <
p2 then the cell with smaller activity loses it even
further while the cell with larger activity gains it.
The signs are correct in the paper, and the part has
been carefully explained in the companion paper of
Hinow et al.
3. P. 9. What is the biological basis of the two thresh-
olds, δmin and δmax?
The mentioned thresholds are a conjecture introduced
to investigate whether biological data contained con-
straints in the transferred quantity when fitted with the
proposed model. See answer to general comment 3.
4. P. 14, lines 6-7 and p. 18, lines 2-3. Please explain
in more detail the interpretation of coefficient τ. Is P-gp
transfer thought of as some kind of Poisson process?
See also general comment 3.
Yes, the time between transfers is assumed to follow an
exponential law. This part is now contained in the
paper; see assumption (A2) page 8.
5. P. 15, lines 5-7, Figure 8B and p. 26, legend to Fig-
u r e8 B .W h e r ed o e st h ef u n c t i o nr(p) displayed in Fig-
ure 8B come from? Is it determined experimentally?
This function has been established empirically given
that it is known that resistance increases as a function of
efflux activity which depends on the expression of P-gp
(see ref 15, 39 and 40). However, there is no precise study
linking the number of P-gp copies at the membrane and
the efflux activity. It has to be considered that P-gp pump-
ing is regulated in the minute range, at least by the phos-
phorylation state of the protein. As a consequence for a
given cell at a particular time, a heterogeneous popula-
tion of P-gps, with pumping activities varying from 0 to a
maximal rate, can coexist in the membrane.
6. P. 24, legend to Figure 3, lines 1-2 from below.
Where are these “vertical solid lines"?
It was corresponding to an older version of the figure.
This sentence has been removed.
7. P. 25, legend to Figure 5. Please explain the role
and selection of quadrants in more detail.
This whole legend has been re-written for clarification.
8. P. 25, legend to Figure 6. What are the cell volumes
matched to? Give the matching volumes or a reference.
This whole legend has been re-written for clarification.
This particular issue is developed in the result section
p12 lines 1-5 from below
9. P. 27. Check the estimates for δmin and δmax.
Shouldn’t they be 1.4 and 1.9? What are the units?
It is correct in the paper. The confusion comes from the
fact that we used for numerical simulation log(p) in Fig-
ure 6(as well as for the numerical simulations) while in
Table 1the result is expressed only using p. Figure 6has
been corrected.
We thank the referee to point out this problem!
10. P.35, Figure 7. Fluorescence counts are reported
on the log scale. Were parameters estimated on the
same scale? Changing scale may affect the estimates of
model parameters.
See the answer of point 9 above.
3. Stylistic Comments
1. P. 5, line 10. The paper denoted [ref] is not specified.
This work is submitted. The given reference is related
to an oral communication based on the study.
2. Use a uniform name for the cell line MCF-7/
DOXO. In some places in the text it is called MCF-7/
doxo, see e.g. pp. 6 and 7.
We harmonized the name of cell line to MCF-7/Doxo
throughout the text
3. P. 6, line 2 from below. What is S.E.M.?
It is the standard error of the mean, now specified in
the text.
4. P. 8. The role and nature of coefficient (or function)
h was never explained.
All coefficients, including coefficient h, are exposed in
table 1.
The function h has been removed.
5. P. 8, line 7 from below. “describe” should be
“describes”.
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6. P. 8, last line. Delete “of” in “transfer of operator T”.
Ok, this has been deleted
7. P. 14, line 6 from below. What is “volumes of
distribution"?
T h ev o l u m eo fd i s t r i b u t i o ni sap h a r m a c o l o g i c a lc o n -
cept used to quantify the distribution of a drug between
plasma, extracellular fluid, intracellular fluid and other
compartments of the body after administration. This
concept is useful for studies carried out in vivo.
8. P. 18, lines 4-5 from below. The phrase “biological
data as well as modelized transfer parameters suggest an
organized quantal trogocytosis of P-gp” is very obscure.
What is the meaning of the words “modelized” and
“quantal"?
The sentence as been modified as following: In this
respect, biological data as well as transfer parameter f
suggest an organized quantal transfer of P-gp, in which
the minimum unit of exchange would probably consist in
a cluster of several copies of the transporter.
9. P. 19, line 4. Shouldn’t “administrated” be changed
to “administered"?
Ok, this has been changed.
10. P. 19, lines 7-8. What does it mean “separating the
injection to the measures"?
In some studies, the effective doxorubicin concentration
in the tumor environment is followed after intravenous
administration of a dose of the drug. Given that doxorubi-
cin is distributed in several physiological compartments,
metabolized and excreted (pharmacokinetics), its concen-
tration in the tumor decreases over time and is all the
more low than the time separating the i.v. infusion to the
measure is high. The sentence has been slightly modified.
1 1 .P .2 0 ,r e f5 .V o l u m en u m b e ra n dp a g e sa r e
missing.
Ok, Volume number and pages have been added.
12. P. 25, line 9. D-E should be D-F.
Ok, this has been changed.
13. P. 25, line 10. Change “analysis” to “analyses”.
Ok, this has been changed.
The recommendations of the referees were most helpful
to us in the improvement of this manuscript.
Reviewer 2: Anna Marciniak-Czochra, University of
Heidelberg, Institute of Applied Mathematics, Heidel-
berg, Germany
The paper is devoted to an interdisciplinary study of
the dynamics of cancer cell drug resistance induced by
the expression of the drug efflux protein, P-gp. A math-
ematical model is developed to investigate and validate
the hypothesis of cell-to-cell transfer of resistance. The
model describes the dynamics of cancer cell population
structured by the level of P-gp activity corresponding to
the resistance level. It is expressed in the form of a dif-
fusion - drift equation with a nonlocal reaction term
describing the transfer between cell subpopulations hav-
ing different levels of P-gp activity. The model is cali-
brated and validated based on in vitro experiments with
co-cultures of drug-resistant and drug-sensitive human
breast carcinoma cells. The model is interesting and
shows the evolution of the resistance structure in cancer
cell population. Model predictions are compared to
experimental observations and biologically relevant con-
clusions are drawn.
I recommend the manuscript for publication in Biol-
ogy Direct after minor revisions.
I think that for completeness of paper it would be
good to clarify:
1. What is the function h(p)?
This question is related to a comment of Reviewer
1: “The paper deals with the model of P-gp transfer with
ε = h = 0. Given the predominantly biological readership
of the journal, I think it would be better to omit these
terms in the model and refer the reader to paper [20] for
a more general model accounting for diffusion and drift”.
We agree with both referees, and we modified the sys-
tem accordingly to the comment.
2.Why is spatially homogeneous approach correct?
Are there any mixing conditions imposed in the experi-
mental setting? Or it is just a first approach ? Do the
authors expect that including spatial effects will influ-
ence the results? It would be good to comment on this
issue, when model is introduced.
Of course, this is a first approach. From a biological
point of view, there is a lot to do in order to give an
underlying mechanism for P-gp transfers and several
directions have to be explored. Another manuscript will
be submitted soon concerning mechanistic. A comment
as been added p10 on this issue.
3.How important is the “diffusion” process included in
the model? How large is
ε? Figure 7 showing that there exist no cells with
some small levels of P-gp
activity suggests that such diffusion process is very
small, if any.
The term ε has been removed
Minor remarks
1. The quality of Figures 4, 6, 8, 9 is not satisfactory, in
particular fonts are too small.
Quality of mentioned figures has been enhanced.
Figure 4 is now Figure 3 CD
Figure 6 is now Figure 5
Figure 8 is now Figure 7
Figure 9 is now Figure 8
2. The description of Figure 3 is confusing; what is (C)
and (D)?
It was corresponding to an older version of the figure.
This whole legend has been re-written for clarification.
3. On p.5 the reference is missing
Pasquier et al. Biology Direct 2011, 6:5
http://www.biology-direct.com/content/6/1/5
Page 16 of 18This work is submitted. The given reference is related
to an oral communication based on the study.
4. P. 11, line 8 from below: it is written that the peak
of activity is shifted to the left towards the region of
higher activity. Is it correct? It seems that “left” means
“lower activity”.
The description is correct. In fact, in these experiments,
the cells were loaded with a fluorescent dye that is a sub-
strate of the efflux pump protein. As a consequence, cells
expressing a low activity level accumulate intracellular
fluorescence and are located in the right part of the graph
after analysis, in region of high fluorescence light (FL). On
the contrary, cells exhibiting higher activity levels actually
efflux the dye and are shifted to the left, a region corre-
sponding to less intracellular fluorescence and thus to
higher pumping activity. This is given p12, line 5 from
below in the revised version of the manuscript.
Reviewer 3: Marek Kimmel, Houston, United States
of America
The paper concerns the important mechanism of hori-
zontal transfer of agents of multiple drug resistance
among cancer cells. Based on their own experiments
and published data, the authors designed a mathematical
model kinetics of which are consistent with the observa-
tions. The mathematical model, in the form of a Boltz-
man-type equation, will serve as a realistic component
for models of chemotherapy. The current version of the
paper has been improved based on referees’ remarks.
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